Dr. Sallinen is currently working on a big, multidisciplinary project called Digital Health Revolution (DHR) funded by Tekes as a national strategic initiative. The vision of the DHR initiative is that future healthcare strategies will evolve in a direction which allows citizens to control and make use of their personal data to improve their overall health and wellness. Dr. Sallinen is in charge of a proof-of-concept wellness study which is performed as part of the DHR project. This next-generation health and wellness study presents principles of P4 (preventive, predictive, personalized, participatory) medicine. It aims at deep systems wellness profiling in a holistic and increasingly real-time manner in order to find personal and meaningful interventions as early as possible to better maintain health over ones lifetime. To accomplish this Dr. Sallinen integrates her unique educational background, years of practical experience in coaching people, and her personal interest in health and wellbeing.
Wessman M, Forsblom C, Kaunisto MA, Söderlund J, Ilonen J, Sallinen R, Hiekkalinna T, Parkkonen M, Maxwell AP, Tarnow L, Parving HH, Hadjadj S, Marre M, Peltonen L, Groop PH; FinnDiane Study Group (2011). Novel susceptibility locus at 22q11 for diabetic nephropathy in type 1 diabetes. PLoS One 6, e24053.
Hoverfelt A, Sallinen R, Söderlund JM, Forsblom C, Pettersson-Fernholm K, Parkkonen M, Groop PH, Wessman M; FinnDiane Study Group (2010) DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes. Diabetologia 53, 1903-1907.
Sallinen R, Latvanlehto A, Kvist AP, Rehn M, Eerola I, Chu M-L, Bonaldo P, Saitta B, Bressan GM, Pihlajaniemi T, Vuorio E, Palotie A, Wessman M, Horelli-Kuitunen N (2001) Physical mapping of mouse collagen genes on Chromosome 10 by high-resolution FISH. Mammal Genome 12, 340-346.
Sallinen R, Vihola A, Bachinski LL, Huoponen K, Haapasalo H, Hackman P, Zhang S, Sirito M, Kalimo H, Meola G, Horelli-Kuitunen N, Wessman M, Krahe R, Udd B (2004) New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 14, 274-283.
Sallinen R, Kaunisto MA, Forsblom C, Thomas M, Fagerudd J, Pettersson-Fernholm K, Groop PH, Wessman M; Finnish Diabetic Nephropathy Study Group (2010) Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension. Ann Med 42, 296-304.